SUSTAIN FORTE Trial (Semaglutide 2mg) The SUSTAIN FORTE trial showed that Semaglutide 2mg achieved greater HbA1c reduction compared to Semaglutide 1mg, leading to approval of the 2mg dose for patients requiring additional glycemic control
Diabetes, Obesity and Metabolism 2021;23(6):12621271
Furthermore, semaglutide exhibits positive effects on lipid levels, contributes to lower systolic blood pressure, and mitigates diabetes-associated chronic inflammation [5, 9]
doi: 10.1007/s00415-023-11706-1 23
Helps rejuvenate tired-looking skin
Cobalamin deficiency results in the decrease of this conversion, resulting in high plasma levels of homocysteine, which is associated with a higher risk of cerebrovascular disease, depression, dementia, cellular stress, and apoptosis (64, 70)